Marios Giannakis - Department of Medical Oncology, Dana-Farber Cancer Institute

Cancer epidemiology, biomarkers & prevention a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncologyno. 4 (2025): 568-577

Cited0Views0WOSBibtex

A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

CANCER IMMUNOLOGY RESEARCHno. 1 (2025): 9-22

Cited0Views0WOSBibtex

Supplementary Figure 3 from <i>ras/raf</i> Comutation and <i>erbb2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

openalex

Cited0Views0Bibtex

Supplementary Figure 4 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

crossref（2024）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn